A PHASE 1 CLINICAL TRIAL OF PYC-003 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

A PHASE 1 CLINICAL TRIAL OF PYC-003 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Anja Stirnweiss anja.stirnweiss@pyctx.com PYC Therapeutics Pre-clinical Perth Australia *

Co-author 2

Aron Chakera Aron.Chakera@health.wa.gov.au PYC Therapeutics Clinical Perth Australia - Sir Charles Gairdner Hospital Renal Medicine and Transplantation Perth Australia

Co-author 3

Jessica Stevenson jessica.stevenson@pyctx.com PYC Therapeutics Clinical Operations Sydney Australia -

Co-author 4

Vanessa Neve vanessa.neve@pyctx.com PYC Therapeutics Clinical Operations Sydney Australia -

Co-author 5

Genevieve Syn genevieve.syn@pyctx.com PYC Therapeutics Pre-clinical Perth Australia -

Co-author 6

Anna Mills anna.mills@pyctx.com PYC Therapeutics Pre-clinical Perth Australia -

Co-author 7

Clarissa McDonagh clarissa.mcdonagh@pyctx.com PYC Therapeutics Pre-clinical Perth Australia -

Co-author 8

Bridget Fils bridget.fils@pyctx.com PYC Therapeutics Pre-clinical Perth Australia -

Co-author 9

Maria Kerfoot maria.kerfoot@pyctx.com PYC Therapeutics Non-clinical Perth Australia -

Co-author 10

Adam Martin adam.martin@pyctx.com PYC Therapeutics CMC Perth Australia -

Co-author 11

Subrata Das subrata.das@pyctx.com PYC Therapeutics CMC Perth Australia -

Co-author 12

Sri Mudumba sri.mudumba@pyctx.com PYC Therapeutics Pre-clinical Perth Australia -

Co-author 13

Paula Cunningham paula.cunningham@pyctx.com PYC Therapeutics Pre-clinical Perth Australia -

Co-author 14

Co-author 15